Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. The aim of this report is to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations to audit current practices against updated NICE guideline recommendations, and to estimate the financial and resource implications of prescribing SGLT-2s to a wider population.
A forthcoming addendum to this publication will estimate the gap between current prescribing of SGLT-2 inhibitors and the number of people with type 2 diabetes who are estimated to be eligible for treatment. Three versions of this addendum will be published covering the North East and Cumbria, Greater Manchester, and Yorkshire and the Humber regions.
Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBl and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2020 to March 2023
Budget impact of metformin 1g immediate release tablet prescribing
The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g IR tablets across the ICSs in the North East & Yorkshire region and Greater Manchester.
Formulary assessment – Glucagon (Ogluo)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Comparison of DPP-4 inhibitors (Gliptins)
Comparison documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.
There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Formulary assessment – estradiol/progesterone (Bijuve) for HRT
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
A New Drug Evaluation is also available on this topic. New Drug Evaluations are concise, structured evidence reviews which cover efficacy, safety, place in therapy, and cost.
Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Download the full review below to read more.

NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making.
Formulary assessment – estradiol spray (Lenzetto)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Formulary assessment – testosterone 2% gel (Tostran) in post-menopausal women
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes mellitus in adults, adolescents, and children aged >1 year. This publication reviews its efficacy and safety, and the limitations of the evidence.